By physician referral or invitation only

A Phase 3, Randomized, Double-Blind, Placebo -Controlled, 3-Arm, 3-Period Study to Assess the Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis

To test the safety and effectiveness of Cladribine with patients who have Myasthenia Gravis.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

United States (Nationwide)

Additional Study Information

Principal Investigator

James Howard
Neurology-Neuromuscular

Study Type

Clinical or Medical
Interventional

Study Topics

Chronic Conditions

IRB Number

25-0136

ClinicalTrials.gov

NCT06463587

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.